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The effect of the timing of drotrecogin alfa (activated)
(DrotAA) treatment on the outcome of severe sepsis was
recently evaluated, using the integrated clinical trial database
INDEPTH. The evaluation demonstrated an association
between earlier treatment (i.e. treatment within 24 hours of
the appearance of first organ dysfunction) and lower patient
mortality [1].
We assessed the timing of DrotAA treatment in our own
(mixed) intensive care unit over a 3-year period. We selected
all patients treated with commercial DrotAA since its
availability in The Netherlands. Patients were treated with
DrotAA according to the national guidelines [2].
As the results presented in Table 1 show, patients treated
within 24 hours were younger and more often had pneumo-
sepsis (45% versus 9%, P = 0.03), which was due to
community-acquired pneumonia in 12 out of 14 cases (86%).
Streptococcus pneumoniae was the most frequently involved
pathogen in these pneumonia patients (seven of 12 cases,
58%). Notably, and in contrast to the analysis of the
INDEPTH data, hospital mortality rates were comparable
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DrotAA = drotrecogin alfa (activated).
Table 1
Baseline patient characteristics based on the time to treatment
Parameter 0–24 hours (n = 29) >24 hours (n = 11) P value
Age (years) 51.5 ± 17.6 67.4 ± 9.9 0.008a
Male sex  13 (45%) 3 (27%) 0.31b
Acute Physiology and Chronic Health Evaluation II score 23.9 ± 5.5 26.9 ± 9.8 0.22a
Time from first organ dysfunction to start of treatment (hours) 12.2 ± 6.8 45.7 ± 21.8 <0.0001a
Number of organ dysfunctions 3.6 ± 1.2 3.3 ± 1.3 0.55a
Mechanical ventilation 25 (86%) 11 (100%) 0.19b
Vasopressors 28 (97%) 10 (91%) 0.47b
Recent surgery 8 (28%) 6 (55%) 0.13b
Primary site of infection
Respiratory system 13 (45%) 1 (9%) 0.03b
Abdominal 8 (28%) 5 (45%) 0.28b
Urogenital 2 (7%) 2 (18%) 0.29b
Other 6 (2%) 3 (27%) 0.66b
Data presented as mean ± standard deviation or as n (%). aStudent’s t test. bChi-square test.Page 2 of 2
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between early treatment and late treatment (38% versus
36%, P = 0.93).
In this small study evaluating DrotAA treatment practice in our
intensive care unit, patients treated earlier were younger and
more often had community-acquired pneumonia. Given that
patients with community-acquired pneumonia seem to benefit
most from DrotAA treatment [3], it would be interesting to
identify differences in primary sites of infection between early
treatment and late treatment within the INDEPTH data.
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